Quarterly Activities/Appendix 4C Cash Flow Report

Open PDF
Stock HITIQ Ltd (HIQ.ASX)
Release Time 30 Jan 2026, 10:25 a.m.
Price Sensitive Yes
 HITIQ Reports Quarterly Activities and Cash Flow
Key Points
  • Launched PROTEQT® North American market strategy through Canadian distribution partnership
  • Entered national retail distribution with Rebel, Australia's leading sporting goods retailer
  • PROTEQT® technology selected for Australian Research Council funded brain injury research program
Full Summary

HITIQ Limited (ASX: HIQ) continued to execute on its transition from technology validation to commercial deployment during the December 2025 quarter, with meaningful progress across retail, international markets, research validation and strategic partnerships. The quarter was highlighted by the formal launch of HITIQ's North American market strategy through an exclusive Canadian distribution agreement, providing immediate access to Canada's extensive collision-sport ecosystem and establishing a scalable entry point into the United States. Domestically, HITIQ commenced national retail distribution with Rebel, representing the Company's first major Australian consumer retail rollout. HITIQ also continued to build its research and institutional credentials, with PROTEQT® selected for inclusion in a major Australian Research Council-funded brain injury research program. Strategic partnerships continued to expand beyond traditional sporting channels, with the execution of a world-first insurance integration partnership with Sportscover. During the quarter, HITIQ successfully completed an oversubscribed placement raising approximately $925,000 before costs. Looking ahead, the Company will focus on scaling retail distribution, converting international validation and research programmes into recurring commercial contracts, and expanding PROTEQT® adoption across institutional, insurance and defence-aligned channels.

Outlook

Looking ahead, the Company will focus on scaling retail distribution, converting international validation and research programmes into recurring commercial contracts, and expanding PROTEQT® adoption across institutional, insurance and defence-aligned channels.